Nobody is right or wrong. The market is not what we think or want we want. All we can do is to try our best to target certain counter based on news in short what is risk appetite
Taurx present the data in Ad pd conference 2024 in portugal .. many bio medical company n Ad Pd reseacrh team will attend the conference . Don't worry only positive report wil b present if not they wil absent tht conference
We already know the past results were positive, and were promising, the additional data is being presented can only be positive, otherwise they would not go through this process of expense to present inclusive data! Simple logic…and don’t forget they have already applied for CA ….in my opinion it is already case of When and not of If…..the process to marketing the product and generating revenue is a fairly long one. That said the market is forward looking and investors will begin to make the move early, as suggested by Maybank the strategy could be to invest early or have a good position early …given that Genting is below valuation in May case without Taurx it makes sense to invest at this pricing point. Some folks will trade but the better option is to invest and wait surely,….it is a gamble worth taking ….all stock investment is a gamble.
Your analysis is logical, agreed. (Taurx present the data in Ad pd conference 2024 in portugal .. many bio medical company n Ad Pd reseacrh team will attend the conference . Don't worry only positive report wil b present if not they wil absent tht conference)
Maybank analyst say only blue sky scenario will go rm9++! Positive result will not get blue sky scenario! We need Strong Strong Positive result only can get rm9++! Don't forget they need to compete with many type of medicine
RM9+ is a dream now, will take long time to realize. Drug approval is a long process and affected by science, politics, international top fund interests.........
Assuming the conference is a total success, just hope to hold above 5.20 after a short burst to maybe 5.40 Still many months away from any black and white approval in a smaller market
1. Results will be good otherwise no point presenting at conference. Given. 2. It's not time to go crazy high yet, that will come if approval is gotten, not from sharing of results in conference. 3. Traders will leverage on this for quick buck, hence you see the volatility. Given. 4. Conclusion, Stay Calm :)
Previous round of 3rd Phase testing result was announced in Bursa for Boss LKT selling! why this round, he is so quiet?Probably outcome result is good!
Why LKT selling (1/Jun 2022) LKT wanted to tender the incomplete cruise ship Global Dream that was being built by MV Werften, Germany. But eventually Disney Cruise Line gave the best offer & acquired it.
GENTING & GENM are no longer blue chips... gambling stocks now...no fundamental etc... The companies changes alot with the secong generation taking over, low interest, no share bonus, and boss pump and dump with news...cheapskate stocks now
they are just like other gambling stocks in BURSA...no more investing driven, trading driven...buy low and sell when got profit...follow the LKT... these are cheapskate now..
not sure why, maybe boss no longer prioriotizing prospect of GENTING and GENM Hhere...due to hopeless political scenario...maybe boss eyeing somewhere else and only take this GENTING and GENM here like gambling stocks
DestinyL ,TauRx is not a charity non profit organization..Ad PD conference is a event tht take chance to promote ur product and show to everyone who interest in Ad Pd the prove and evidence Traurx medicine can help the people... not sure u expert in marketing or not ,so r u sure they going to bring the failure test report to portugal,and choose to tell ppl in the conference "the test is fail "??? jst think abt it hehehehehehe.
2022: - RM299.9 million 2023: RM929.2 million 2024: RM1,709 million (forecast) 2025: RM1,934 million (forecast) Considering the poor financial performance in 2022 and 2023, with this kind of lousy financial report.. how to expect GenB's share price could rise. However, there's optimism that the share price will recover in 2024 and 2025, given the forecasted improvements in net income.
Clinical practice has been waiting decades to uncover meaningful advancements to address unmet needs of people with AD. These new results further support the importance of NfL as an AD biomarker both for diagnosis and measurement of treatment effect.”
Those it mean lucidity is the only one of the kind now on the future market ? Others only help few months and cant be use anymore!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
keyman
524 posts
Posted by keyman > 2024-03-06 19:28 | Report Abuse
Moreover, I hope heartily the coming news will be positive as most of my.... Sorry to say that... Beloved and respectful Sifus still holding it. 👍😉